文献速递其他结缔组织病

从疑似系统性硬化症进展为确诊系统性硬化症及抗拓扑异构酶I抗体的作用

Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies.
PubMed 文献 · RMD Open · 2023-01-01

该文献综述结合Leiden CCISS队列分析,探讨疑似极早期系统性硬化症(SSc)中抗拓扑异构酶I抗体(ATA)的患病率及其对进展为确诊SSc的作用;纳入研究显示疑似极早期SSc中ATA患病率远低于符合ACR/EULAR 2013标准人群,随访1-15年仅52%进展为确诊SSc,ATA-IgG水平在进展更快的ATA阳性SSc患者中趋于更高。

要点

  • 疑似极早期SSc中ATA患病率远低于符合ACR/EULAR 2013标准的人群。
  • 疑似极早期SSc随访1-15年仅52%进展为确诊SSc。
  • 进展更快的ATA阳性SSc患者ATA-IgG水平趋于更高。

核心结论

  • 虽提示ATA在疾病进展中可能起作用,但仍需更多关于疑似极早期SSc中ATA应答的研究。

研究设计与样本

  • 本文为文献综述,并在Leiden联合系统性硬化症关怀(CCISS)队列中评估ATA应答与雷诺现象(RP)起病至首个非RP症状出现时间之间的关联。
  • 研究识别Leiden CCISS队列中所有ATA阳性但不满足ACR/EULAR 2013标准的疑似极早期SSc患者,发现例数非常少,因而触发文献检索。

主要发现

  • 纳入研究显示,疑似极早期SSc中ATA患病率远低于符合ACR/EULAR 2013标准的人群。
  • 疑似极早期SSc患者随访1-15年后,仅52%进展为确诊SSc。
  • 在ATA阳性SSc患者中,疾病进展更快的患者ATA-IgG水平趋于更高。

关键数值与推荐

  • 疑似极早期ATA阳性SSc定义为ATA阳性但不满足ACR/EULAR 2013标准。
  • 疑似极早期SSc随访1-15年后仅52%进展为确诊SSc。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • Leiden CCISS队列中ATA阳性但不满足ACR/EULAR 2013标准的疑似极早期SSc患者例数非常少。
  • 仍需更多关于疑似极早期SSc中ATA应答的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Early diagnosis of systemic sclerosis (SSc) is important to start therapeutic interventions timely. Important risk factors for progression to SSc are the SSc-specific autoantibodies, of whom anti-centromere antibodies (ACA) and anti-topoisomerase I antibodies (ATA) are the most frequent. ATA is associated with a severe disease course. A more detailed characterisation of the ATA-response in SSc might increase insights in preclinical disease stages and improve prognostication. To address this we identified all patients with suspected very early ATA-positive SSc, defined as all patients who are ATA-positive not fulfilling American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) 2013 criteria, in the Leiden Combined Care in Systemic Sclerosis (CCISS)-cohort and found very low numbers. METHODS: This triggered us to search the literature on the ATA prevalence in patients with suspected very early SSc and contribution of the SSc-specific autoantibodies to progression from suspected very early to definite SSc. To increase insights on the ATA-response in suspected very early SSc, we then evaluated the association between the ATA-response and time between onset of Raynaud's phenomenon (RP) and first non-RP symptom, as a proxy for progressing to definite SSc, in all patients with ATA-positive SSc from the Leiden CCISS-cohort. RESULTS: In short, included studies show that prevalence of ATA is much lower in suspected very early SSc than in populations fulfilling ACR/EULAR 2013 criteria. After 1-15 years of follow-up, only 52% of the patients with suspected very early SSc progress to definite SSc. ATA-IgG levels tend to be higher in patients with ATA-positive SSc with more rapid disease progression. CONCLUSION: Although a role of ATA in disease progression is suggested, more studies on the ATA response in suspected very early SSc are warranted.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Liem SIE, Neppelenbroek S, Fehres CM, et al. Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies. RMD Open. 2023. PMID: 36746531. doi:10.1136/rmdopen-2022-002827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。